Squarepoint’s Intellia Therapeutics NTLA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-209,983
| Closed | -$2.69M | – | 4801 |
|
|
2026
Q1 | $2.69M | Buy |
209,983
+67,248
| +47% | +$857K | ﹤0.01% | 1972 |
|
|
2025
Q4 | $1.28M | Buy |
+142,735
| New | +$1.96M | ﹤0.01% | 2399 |
|
|
2025
Q2 | – | Sell |
-42,959
| Closed | -$305K | – | 4872 |
|
|
2025
Q1 | $305K | Sell |
42,959
-58,458
| -58% | -$590K | ﹤0.01% | 3725 |
|
|
2024
Q4 | $1.18M | Buy |
101,417
+37,533
| +59% | +$586K | ﹤0.01% | 2901 |
|
|
2024
Q3 | $1.31M | Buy |
63,884
+50,604
| +381% | +$1.17M | ﹤0.01% | 2393 |
|
|
2024
Q2 | $297K | Sell |
13,280
-232,496
| -95% | -$5.54M | ﹤0.01% | 3436 |
|
|
2024
Q1 | $6.76M | Buy |
245,776
+235,739
| +2,349% | +$6.55M | 0.01% | 1246 |
|
|
2023
Q4 | $306K | Buy |
+10,037
| New | +$288K | ﹤0.01% | 3340 |
|
|
2023
Q3 | – | Sell |
-5,314
| Closed | -$217K | – | 4094 |
|
|
2023
Q2 | $217K | Sell |
5,314
-268,890
| -98% | -$10.9M | ﹤0.01% | 3174 |
|
|
2023
Q1 | $10.2M | Buy |
274,204
+183,080
| +201% | +$7.18M | 0.04% | 539 |
|
|
2022
Q4 | $3.18M | Buy |
91,124
+84,834
| +1,349% | +$4.03M | 0.01% | 1090 |
|
|
2022
Q3 | $352K | Buy |
+6,290
| New | +$390K | ﹤0.01% | 2391 |
|
|
2022
Q2 | – | Sell |
-56,057
| Closed | -$4.07M | – | 3219 |
|
|
2022
Q1 | $4.07M | Buy |
+56,057
| New | +$4.75M | 0.02% | 807 |
|
|
2021
Q4 | – | Sell |
-97,871
| Closed | -$13.1M | – | 3422 |
|
|
2021
Q3 | $13.1M | Buy |
97,871
+90,240
| +1,183% | +$13.7M | 0.04% | 422 |
|
|
2021
Q2 | $1.24M | Buy |
+7,631
| New | +$594K | ﹤0.01% | 1480 |
|
|
2021
Q1 | – | Sell |
-44,899
| Closed | -$2.44M | – | 3463 |
|
|
2020
Q4 | $2.44M | Sell |
44,899
-28,323
| -39% | -$1.03M | 0.02% | 837 |
|
|
2020
Q3 | $1.46M | Buy |
73,222
+19,350
| +36% | +$403K | 0.02% | 801 |
|
|
2020
Q2 | $1.13M | Buy |
+53,872
| New | +$915K | 0.02% | 868 |
|
|
2019
Q2 | – | Sell |
-68,150
| Closed | -$1.16M | – | 2580 |
|
|
2019
Q1 | $1.16M | Sell |
68,150
-7,349
| -10% | -$110K | 0.01% | 1024 |
|
|
2018
Q4 | $1.03M | Buy |
75,499
+42,999
| +132% | +$799K | 0.01% | 907 |
|
|
2018
Q3 | $930K | Buy |
32,500
+5,671
| +21% | +$165K | 0.01% | 1026 |
|
|
2018
Q2 | $734K | Sell |
26,829
-16,571
| -38% | -$401K | 0.01% | 1017 |
|
|
2018
Q1 | $915K | Buy |
43,400
+10,917
| +34% | +$268K | 0.01% | 840 |
|
|
2017
Q4 | $624K | Buy |
+32,483
| New | +$750K | 0.01% | 1069 |
|
Other funds holding NTLA
AIM
RCM
RP
Squarepoint's NTLA Position: Q2 2026 in Review
Squarepoint sold out of Intellia Therapeutics (NTLA) in Q2 2026, closing a stake of 209,983 shares — an estimated $2.69M sold.
Squarepoint first reported a position in NTLA in Q4 2017 and held it in 24 quarters. The position peaked at $13.1M in Q3 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.
- Squarepoint reported no remaining Intellia Therapeutics position as of Q2 2026 after selling out during the quarter.
- Squarepoint sold 209,983 Intellia Therapeutics shares in Q2 2026, an estimated $2.69M.
- Squarepoint first reported a position in Intellia Therapeutics in Q4 2017 and held it in 24 quarters.
- Squarepoint's Intellia Therapeutics position peaked at $13.1M in Q3 2021.
- 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.
Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.